



GI connect

POWERED BY COR2ED

Supported by an Independent Educational Grant from



MEETING SUMMARY

ESMO 2016 – COPENHAGEN, DENMARK
OCTOBER 7TH TO 11TH 2016

BY PROF. ARMIN GERGER – DIVISION OF CLINICAL
ONCOLOGY, MEDICAL UNIVERSITY OF GRAZ, AUSTRIA

CANCERS OF THE LIVER, SMALL INTESTINE
AND PANCREATIC TRACT

NAPOLI-1

- Phase III-metastatic pancreatic cancer (previously gemcitabine-based CTX)
- Nal-IRI +-5-FU/leucovorin vs 5-FU/leucovorin
- Final analysis (data cut-off Nov 2015)
- OS improvement with nal-IRI + 5-FU/leucovorin from 4.2 to 6.2 months (HR 0.75)
- ORR 17 vs 1%
- No new safety concerns
- New treatment option

CHECKMATE-40

- Phase 1/2: Nivolumab in advanced HCC
- Safety and preliminary efficacy
- Treatment related adverse events in 65% of the patients
- Response regardless of underlying HCC aetiology
- Median OS data not mature
- 9 months OS rate 70.8%
- Nivolumab favourable to historic BSC data

GENOMIC PROFILING IN SMALL BOWEL ADENOCARCINOMAS

- Prospectively 385 patients analysed
- Hybrid capture based genomic profiling
- MSI-high status more frequent than in CRC and GC
- May benefit from anti-PD1 therapies
- Allowed identification of targetable genomic alterations



GI connect

POWERED BY COR2ED

Supported by an Independent Educational Grant from

